KEY TAKEAWAY: The idiocy of raising a price on a prescription medication over 5000% and the current series of articles on J&J’s marketing of Risperdal is enough to turn even supporters to haters of big pharma.
SUMMARY: The Huffington Post Highline and journalist Steven Brill today began publishing “America’s Most Admired Law Breaker,” a 15-part series detailing how Johnson & Johnson took an anti-psychotic drug, Risperdal, initially intended only for the treatment of psychotic disorders, and put it in the hands of children and the elderly in violation of FDA restrictions.
KEY TAKEAWAY: The headlines, when it comes to the pharma business, have not been kind with an emphasis on everything to high drug prices to declining sales of biopharma companies that were once the darlings of Wall Street. Data won’t help, it’s time to walk the walk .
KEY TAKEAWAY: As more patients go online social media IS a part of the conversation. What we don’t really know is how much social media weighs in the healthcare treatment choices patients make but at this point in time biopharma cannot continue to ignore this channel.
KEY TAKEAWAY: DTC marketing is meant to drive new Rx’s but insurers are having a bigger say about which drugs patients get. Can the drug industry make peace with insurers or is it going to be a battle of war between profits, Wall Street and patients.